1,044 results match your criteria Prostate Cancer - Management of Localized Disease


Bringing prostate cancer germline genetics into clinical practice.

J Urol 2019 Feb 5. Epub 2019 Feb 5.

Department of Urology, University of Michigan, Ann Arbor, MI.

Purpose: Until recently, the role of germline genetics in prostate cancer care was not well defined. While important questions remain, here we review the current understanding of germline genetic alterations related to prostate cancer and discuss the clinical implications for genetic counselling, genetic testing, early detection, and treatment in men with these mutations.

Materials And Methods: We performed a PubMed search for English Language articles published since 2001 with keywords "germline mutations", or "BRCA", or "family history", or "prostate cancer genetics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000137DOI Listing
February 2019

Green tea extract for prevention of prostate cancer progression in patients on active surveillance.

Oncotarget 2018 Dec 28;9(102):37798-37806. Epub 2018 Dec 28.

H. Lee Moffitt Cancer Center & Research Institute, GU Oncology MMG, Tampa, FL 33612-9497, USA.

Background: Active surveillance (AS) has evolved as a management strategy for men with low grade prostate cancer (PCa). However, these patients report anxiety, doubts about the possible progression of the disease as well as higher decisional conflict regarding selection of active surveillance, and have been reported to ultimately opt for treatment without any major change in tumor characteristics. Currently, there is a paucity of research that systematically examines alternate strategies for this target population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26519DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340872PMC
December 2018
1 Read

Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer.

Eur Urol 2019 Jan 24. Epub 2019 Jan 24.

Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Institute of Urologic Oncology, University of California, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine, 300 Stein Plaza, Los Angeles, CA 90095, USA. Electronic address:

Multiparametric magnetic resonance imaging (mpMRI) has transformed the management of localized prostate cancer by improving identification of clinically significant disease at diagnosis. Approximately 20% of primary prostate tumors are invisible to mpMRI, and we hypothesize that this invisibility reflects fundamental molecular properties of the tumor. We therefore profiled the genomes and transcriptomes of 40 International Society of Urological Pathology grade 2 tumors: 20 mpMRI-invisible (Prostate Imaging-Reporting and Data System [PI-RADS] v2 <3) and 20 mpMRI-visible (PI-RADS v2 5) tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.12.036DOI Listing
January 2019
1 Read

A Phase II Study Evaluating Bone Marrow-Sparing, Image-guided Pelvic Intensity-Modulated Radiotherapy (IMRT) With Cesium-131 Brachytherapy Boost, Adjuvant Chemotherapy, and Long-Term Hormonal Ablation in Patients With High Risk, Nonmetastatic Prostate Cancer.

Am J Clin Oncol 2019 Jan 22. Epub 2019 Jan 22.

Department of Radiation Oncology.

Purpose/objective(s): Management of localized high-risk prostate cancer remains challenging. At our institution we performed a prospective phase II study of 2 years of androgen deprivation therapy (ADT), pelvic radiation, Cesium (Cs)-131 brachytherapy boost, and adjuvant docetaxel in high risk, localized prostate cancer with a primary endpoint of 3-year disease-free survival.

Materials/methods: Acute/chronic hematologic, gastrointestinal (GI) and genitourinary (GU) toxicities were scored based on the CTCAE v3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000520DOI Listing
January 2019
1 Read

Prognostic Significance for Long-Term Outcomes Following Radical Prostatectomy in Men with Prostate Cancer: Evaluation with Prostate Imaging Reporting and Data System Version 2.

Korean J Radiol 2019 Feb;20(2):256-264

Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Objective: To retrospectively determine whether the use of the Prostate Imaging Reporting and Data System (PI-RADS) version 2 (v2) helps predict long-term outcomes for prostate cancer (PCa) patients following radical prostatectomy (RP).

Materials And Methods: A total of 166 patients with localized PCa evaluated with multiparametric magnetic resonance imaging (mpMRI) at 3T before RP were enrolled. Three groups were created based on PI-RADS v2 score used to predict clinical outcomes: group A, ≥ 3; group B, ≥ 4; group C, 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3348/kjr.2018.0613DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342765PMC
February 2019
1.807 Impact Factor

Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells.

Int J Mol Sci 2019 Jan 8;20(1). Epub 2019 Jan 8.

CHU de Québec⁻Université Laval Research Center, Quebec, QC G1R 2J6, Canada.

Localized prostate cancer (PCa) is often curable, whereas metastatic disease treated by castration inevitably progresses toward castration-resistant PCa (CRPC). Most CRPC treatments target androgen receptor (AR) signaling. However, not all CRPC cells rely on AR activity for survival and proliferation. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1422-0067/20/1/216
Publisher Site
http://dx.doi.org/10.3390/ijms20010216DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337121PMC
January 2019
4 Reads

A phase I pilot study of pre-operative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes.

Int J Radiat Oncol Biol Phys 2019 Jan 6. Epub 2019 Jan 6.

Department of Radiation Oncology, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Techna Institute, University Health Network, Toronto, Canada. Electronic address:

Background: Neoadjuvant radiotherapy (RT) improves disease control in various cancers, and has become an established oncologic treatment strategy. During 2001-2004, we conducted a phase I pilot study assessing the role of short-course pre-operative RT (PreORT) for men with unfavourable intermediate- and high-risk localized prostate cancer. Herein, we present long-term follow-up toxicity and oncologic outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2018.12.054DOI Listing
January 2019
6 Reads

Trend of Surgical Treatment of Localized Renal Cell Carcinoma.

Perm J 2019 ;23

Los Angeles Medical Center, CA.

Introduction: Rapid adoption of robotics has introduced a paradigm change in prostate cancer treatment, with more than 80% of prostatectomies performed robotically in 2015. For treatment of renal cell carcinoma (RCC), this change has not previously been reported. We evaluated trends in surgical management of RCC in Kaiser Permanente Southern California (KPSC) within the last 16 years, especially after adoption of robotics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7812/TPP/18-108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326554PMC
January 2019
1 Read

Incidence, Management, and Clinical Outcomes of Prostate Cancer in Kidney Transplant Recipients.

Exp Clin Transplant 2018 Dec 31. Epub 2018 Dec 31.

From the Department of Urology and Transplant Surgery, Beaumont Hospital, Dublin, Ireland.

Objectives: We reviewed the incidence, management, and survival outcomes of prostate cancer among kidney transplant recipients and compared these characteristics with a national population (nonrecipients).

Materials And Methods: A retrospective study was performed on all kidney transplant recipients from a National Kidney Transplant Centre who were subsequently diagnosed with prostate cancer. Primary outcome variables included comparisons of incidence and 5-year overall survival in kidney transplant recipients versus nonrecipients after treatment of prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6002/ect.2018.0048DOI Listing
December 2018
1 Read

Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management.

Clin Chem 2019 Jan 11;65(1):100-107. Epub 2018 Dec 11.

University College London Cancer Institute, London, UK;

Background: Molecular characterization of tumors could be important for clinical management. Plasma DNA obtained noninvasively as a liquid biopsy could be widely applicable for clinical implementation in biomarker-based treatment strategies.

Content: Prostate cancer is a disease with variable clinical outcomes and molecular features and therefore presents multiple opportunities for biomarker-based treatment optimization. Read More

View Article

Download full-text PDF

Source
http://www.clinchem.org/lookup/doi/10.1373/clinchem.2018.287
Publisher Site
http://dx.doi.org/10.1373/clinchem.2018.287250DOI Listing
January 2019
5 Reads

Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy.

Prostate 2019 Mar 9;79(4):425-432. Epub 2018 Dec 9.

Urological Research Centre, Department of Urology, Vejle Hospital, Vejle, Denmark.

Background: Overtreatment is a well-known clinical challenge in local prostate cancer (PCa). Although risk assessment models have contributed to a better stratification of patients with local PCa, a tailored management is still in its infancy. Over the last few decades, microRNAs (miRNAs) have shown promising results as biomarkers in PCa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23748DOI Listing
March 2019
3 Reads

Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202.

J Clin Oncol 2019 Jan 7;37(3):213-221. Epub 2018 Dec 7.

12 Cedars-Sinai Medical Center, Los Angeles, CA.

Background: In prostate cancer, end points that reliably portend prognosis and treatment benefit (surrogate end points) can accelerate therapy development. Although surrogate end point candidates have been evaluated in the context of radiotherapy and short-term androgen deprivation (AD), potential surrogates under long-term (24 month) AD, a proven therapy in high-risk localized disease, have not been investigated.

Materials And Methods: In the NRG/RTOG 9202 randomized trial (N = 1,520) of short-term AD (4 months) versus long-term AD (LTAD; 28 months), the time interval free of biochemical failure (IBF) was evaluated in relation to clinical end points of prostate cancer-specific survival (PCSS) and overall survival (OS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338393PMC
January 2019

Non-Whole-Gland High-Intensity Focused Ultrasound vs Whole-Gland High-Intensity Focused Ultrasound for Management of Localized Prostate Cancer: 1-Year Oncological and Functional Outcomes.

J Endourol 2019 Feb;33(2):100-106

Department of Urology, Diakonie Klinikum Stuttgart, Stuttgart, Germany.

Objective: The aim of the study was to compare the oncological and functional outcomes in localized prostate cancer patients who received non-whole-gland high-intensity focused ultrasound (HIFU) with those in patients who received whole-gland HIFU therapy.

Patients And Methods: Eighty-six patients from September 2012 to January 2017 in our center were retrospectively analyzed. Oncological outcomes included histological absence of prostate cancer, biochemical disease-free survival (BDFS) as well as the absence of lesions suspected for harboring prostate cancer in multiparametric magnetic resonance imaging (mpMRI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/end.2018.0468DOI Listing
February 2019

Advanced prostate cancer update 2018.

Authors:
Oliver Sartor

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:9-12

Tulane Cancer Center, New Orleans, LA, USA.

The management of advanced prostate cancer today follows a multidisciplinary approach and involves multi-target treatments. The paradigm has shifted from traditional hormonal therapy, surgery and radiation, to the use of chemotherapy, and until recently the development of various immunotherapies and radiopharmaceuticals. Recent advances turn to molecular medicine combining the expertise of molecular pathology and genetics. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13057
Publisher Site
http://dx.doi.org/10.1111/ajco.13057DOI Listing
November 2018
18 Reads

Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer.

Expert Opin Pharmacother 2018 Nov 21:1-10. Epub 2018 Nov 21.

c 2nd Department of Urology, Sismanogleion General Hospital, School of Medicine , National and Kapodistrian University of Athens , Athens , Greece.

Introduction:  Prostate cancer is the most common cancer in men. Regardless of the initial treatment of localized disease, almost all patients develop castration resistant prostate cancer (CRPC). A better understanding of the molecular mechanisms behind castration resistance has led to the approval of novel oral androgen receptor (AR) antagonists, such as enzalutamide and apalutamide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1548611DOI Listing
November 2018
12 Reads

Pattern of care of prostate cancer patients across the Martinique: results of a population-based study in the Caribbean.

BMC Cancer 2018 Nov 16;18(1):1130. Epub 2018 Nov 16.

CHU MARTINIQUE, Pôle de Cancérologie Hématologie Urologie Pathologie, 97200 Fort-de-France, Martinique, France.

Background: The French West-Indies rank first for both prostate cancer incidence and mortality rates. Analyzing diagnostic and therapeutic procedures among patients with prostate cancer, using data from a population-based cancer registry, is essential for cancer surveillance and research strategies.

Methods: This retrospective observational cohort study was based on data from the Martinique Cancer Registry. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-018-5047-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240273PMC
November 2018
11 Reads

[French ccAFU guidelines - Update 2018-2020: Prostate cancer].

Prog Urol 2018 Nov 2;28(12S):S79-S130. Epub 2018 Nov 2.

Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Service d'urologie, hôpital européen Georges-Pompidou, université Paris Descartes, Assistance publique des hôpitaux de Paris (AP-HP), 75015 Paris, France.

Objective: The purpose of the guidelines national committee ccAFU was to propose updated French guidelines for prostate cancer.

Methods: A Medline search was achieved between 2016 and 2018, as regards diagnosis, options of treatment and follow-up of prostate cancer, and to evaluate the different references specifying their levels of evidence.

Results: Epidemiology, classification, staging systems, diagnostic evaluation of prostate cancer are reported. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S11667087183051
Publisher Site
http://dx.doi.org/10.1016/j.purol.2018.08.011DOI Listing
November 2018
16 Reads

Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.

Eur Urol 2019 Mar 31;75(3):515-522. Epub 2018 Oct 31.

Department of Urology, Ochsner Clinic, New Orleans, LA, USA; Queensland School of Medicine, Brisbane, Australia.

Background: Better prostate cancer risk stratification is necessary to inform medical management, especially for African American (AA) men, for whom outcomes are particularly uncertain.

Objective: To evaluate the utility of both a cell cycle progression (CCP) score and a clinical cell-cycle risk (CCR) score to predict clinical outcomes in a large cohort of men with prostate cancer highly enriched in an AA patient population.

Design, Setting, And Participants: Patients were diagnosed with clinically localized adenocarcinoma of the prostate and treated at The Ochsner Clinic (New Orleans, LA, USA) from January 2006 to December 2011. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838183081
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2018.10.028DOI Listing
March 2019
16 Reads

Rethinking active surveillance for prostate cancer in African American men.

Transl Androl Urol 2018 Sep;7(Suppl 4):S397-S410

Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA.

Active surveillance (AS) is a treatment modality for prostate cancer that aims to simultaneously avoid overtreatment and allow for the timely intervention of localized disease. AS has become the de facto standard of care for most men with low-risk prostate cancer. However, few African American (AA) men were included in the prospective observational cohorts that resulted in a paradigm shift in treatment recommendations from active intervention toward AS. Read More

View Article

Download full-text PDF

Source
http://tau.amegroups.com/article/view/20441/20785
Publisher Site
http://dx.doi.org/10.21037/tau.2018.06.19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178310PMC
September 2018
18 Reads

Targeted Prostate Biopsy and MR-Guided Therapy for Prostate Cancer.

Adv Exp Med Biol 2018 ;1096:159-184

Department of Urology, Mayo Clinic, Rochester, MN, USA.

In 2018, the American Cancer Society (ACS) estimates that 164,690 new cases of prostate cancer will be diagnosed and 29,430 will die due to the prostate cancer in the United States (Siegel et al., CA Cancer J Clin 67:7-30, 2018). Many men with prostate cancer are often managed with aggressive therapy including radiotherapy or surgery. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-319-99286-0_9
Publisher Site
http://dx.doi.org/10.1007/978-3-319-99286-0_9DOI Listing
January 2018
11 Reads

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer.

Front Oncol 2018 24;8:397. Epub 2018 Sep 24.

Division of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy.

Management of localized and advanced prostate cancer benefits from several therapeutic options with a surprising improvement in terms of clinical outcome. The selection of patients more likely to benefit from a specific approach still remains a key issue as well as the early identification of patients with aggressive disease which could benefit from a more aggressive treatment strategy. The lack of reliable bio-marker in castration resistant setting able to monitor response to treatment and early inform about tumor progression is an emerging issue. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fonc.2018.00397/
Publisher Site
http://dx.doi.org/10.3389/fonc.2018.00397DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165898PMC
September 2018
18 Reads

The addition of chemotherapy in the definitive management of high risk prostate cancer.

Urol Oncol 2018 11 9;36(11):475-487. Epub 2018 Oct 9.

Department of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, GA; Winship Cancer Institute at Emory University, Atlanta, GA.

In attempt to improve long-term disease control outcomes for high-risk prostate cancer, numerous clinical trials have tested the addition of chemotherapy (CTX)-either adjuvant or neoadjuvant-to definitive local therapy, either radical prostatectomy (RP) or radiation therapy (RT). Neoadjuvant trials generally confirm safety, feasibility, and pre-RP PSA reduction, but rates of pathologic complete response are rare, and no indications for neoadjuvant CTX have been firmly established. Adjuvant regimens have included CTX alone or in combination with androgen deprivation therapy (ADT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.07.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214780PMC
November 2018
2 Reads

Unsuspected Skin Metastasis of Adenocarcinoma of the Prostate in a Patient on Goserelin (Zoladex).

Niger J Surg 2018 Jul-Dec;24(2):138-141

Deparment of Internal Medicine, Nnamdi Azikiwe University, Awka, Nigeria.

Prostate cancer remains the most common noncutaneous cancer in men, especially in this era of prostate-specific antigen assay. Prostate cancer metastases have been known to commonly affect the lymphatics, bones, and lungs. Prostate cancer metastasis to the skin is very rare (<1%) and often signifies a terminal disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/njs.NJS_15_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158991PMC
October 2018

Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.

Int J Oncol 2018 Dec 27;53(6):2503-2517. Epub 2018 Sep 27.

Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.

Prostate cancer (PCa) is a malignant tumor with a high incidence in males. Localized tumors can be treated via surgery or radiation; however, it remains difficult to prevent disease progression. Bromodomain-containing protein 4 (BRD4) is an epigenetic reader protein that binds to acetylated lysine on histones and has been reported to serve critical roles in numerous types of cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2018.4577DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203153PMC
December 2018
9 Reads

Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.

JAMA Oncol 2018 Sep 13. Epub 2018 Sep 13.

Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

Importance: Localized prostate cancer diagnosis and treatment among elderly men who are not likely to benefit represents a potential source of low-value health care services.

Objective: To quantify the costs to the Medicare program associated with detection and treatment of prostate cancer among elderly men in the United States.

Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study uses the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database to identify men 70 years or older diagnosed with localized prostate cancer between 2004 and 2007 and to ascertain Medicare costs associated with diagnosis and workup, treatment, follow-up, and morbidity management of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.3701DOI Listing
September 2018
1 Read

Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment.

Am Soc Clin Oncol Educ Book 2018 May(38):363-371

From the Division of Oncology, University of Utah/Huntsman Cancer Institute, Salt Lake City, UT; Division of Oncology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Division of Hematology/Oncology, University of California-San Francisco, Helen Diller Comprehensive Cancer Center, San Francisco, CA.

The treatment landscape for metastatic castration-sensitive prostate cancer (mCSPC) has rapidly evolved over the past 5 years. Although androgen-deprivation therapy (ADT) is still the backbone of treatment, the addition of docetaxel or abiraterone acetate has improved outcomes for patients with mCSPC and become standard of care. With multiple treatment options available for patients with mCSPC, treatment selection to optimize patient outcomes has become increasingly difficult. Read More

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/EDBK_200967
Publisher Site
http://dx.doi.org/10.1200/EDBK_200967DOI Listing
May 2018
5 Reads

Genetics and biology of prostate cancer.

Genes Dev 2018 09;32(17-18):1105-1140

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer remains largely incurable even after intensive multimodal therapy. The lethality of advanced disease is driven by the lack of therapeutic regimens capable of generating durable responses in the setting of extreme tumor heterogeneity on the genetic and cell biological levels. Here, we review available prostate cancer model systems, the prostate cancer genome atlas, cellular and functional heterogeneity in the tumor microenvironment, tumor-intrinsic and tumor-extrinsic mechanisms underlying therapeutic resistance, and technological advances focused on disease detection and management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/gad.315739.118DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120714PMC
September 2018

Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance.

J Urol 2019 02;201(2):308-314

Purpose: Active surveillance is increasingly used as a management strategy for localized prostate cancer. Coffee intake has been associated with a lower prostate cancer incidence. We assessed whether coffee was associated with disease progression in men on active surveillance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2018.08.048DOI Listing
February 2019
3 Reads

[Correlation of prostate-specific antigen with the progression and metastasis of human prostate cancer].

Zhonghua Nan Ke Xue 2018 May;24(5):457-461

Department of Pharmacology and Toxicology, Shanghai Institute of Planned Parenthood Research / National Evaluation Center for the Toxicology of Fertility-Regulating Drugs, Shanghai 200032, China.

Prostate-specific antigen (PSA) is a biomarker for the diagnosis and management of prostate cancer and involved in the development of prostate cancer and/or its progression from the localized to the metastatic stage. This review presents an overview of the roles of PSA in promoting the progression and metastasis of human prostate cancer and its underlying mechanisms, including its serine protease activity, interaction with the cellular membrane receptor, and suppression of specific immune responsiveness, and also points out some of the key problems to be solved. Read More

View Article

Download full-text PDF

Source
May 2018
12 Reads

New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors.

Int J Mol Sci 2018 Aug 28;19(9). Epub 2018 Aug 28.

Université Clermont Auvergne, GReD, CNRS UMR 6293, INSERM U1103, 28, place Henri Dunant, BP38, F63001 Clermont-Ferrand, France.

Prostate cancer (PCa) incidence has been dramatically increasing these last years in westernized countries. Though localized PCa is usually treated by radical prostatectomy, androgen deprivation therapy is preferred in locally advanced disease in combination with chemotherapy. Unfortunately, PCa goes into a castration-resistant state in the vast majority of the cases, leading to questions about the molecular mechanisms involving the steroids and their respective nuclear receptors in this relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms19092545DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164771PMC
August 2018
12 Reads

Racial variation in receipt of quality radiation therapy for prostate cancer.

Cancer Causes Control 2018 Oct 11;29(10):895-899. Epub 2018 Aug 11.

Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.

Purpose: Racial disparities are apparent in the management and outcomes for prostate cancer; however, disparities in compliance to quality measures for radiation therapy for prostate cancer have not been previously studied. Therefore, the goal of the study was to characterize disparities in the compliance rates with quality measures.

Methods: The comparative effectiveness analysis of radiation therapy and surgery study is a population-based, prospective cohort study that enrolled 3708 men with clinically localized prostate cancer from 2011 to 2012. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10552-018-1065-5
Publisher Site
http://dx.doi.org/10.1007/s10552-018-1065-5DOI Listing
October 2018
13 Reads

Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience.

J Glob Oncol 2018 Jul(4):1-13

Francis A. Asamoah, Shivanshu Awasthi, Puja S. Venkat, Angelina K. Fink, Arash O. Naghavi, Peter A.S. Johnstone, and Kosj Yamoah, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; and Francis A. Asamoah, Joel Yarney, Verna Vanderpuye, Afua Abrahams, James E. Mensah, Evans Sasu, and Samuel N.A. Tagoe, Korle Bu Teaching Hospital, Accra, Ghana, West Africa.

Purpose Data on prostate cancer (PCa) treatment in Africa remains under-reported. We present a review of the management of PCa at the cancer center of the largest tertiary referral facility in Ghana, with emphasis on curative treatment. Methods We retrospectively reviewed data on 1,074 patients seen at the National Center for Radiotherapy and Nuclear Medicine from 2003 to 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.17.00234DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223508PMC
July 2018
14 Reads

Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations.

NPJ Precis Oncol 2018 25;2:15. Epub 2018 Jul 25.

Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO USA.

Prostate cancer (PCa) is the most frequently diagnosed malignancy and second leading cause of cancer mortality in American males. Notably, men of African descent in the United States and Caribbean have the highest PCa mortality rates compared to men with European ancestry. Although current therapeutics are quite potent and effective, disease resistance, progression to metastasis, therapy-associated toxicities and efficacy-related issues in diverse populations develop over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41698-018-0058-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060229PMC
July 2018
2 Reads

Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification.

Oncol Lett 2018 Jul 22;16(1):1357-1365. Epub 2018 May 22.

Department of Surgery, College of Medicine and Medical Sciences, Arabian Gulf University, Manama 329, Kingdom of Bahrain.

Prostate cancer (PCa) is the second most diagnosed malignancy, and the leading cause of cancer-associated mortality among males. Prostate-specific antigen (PSA) has long been used for the detection of PCa. However, PSA levels increase in PCa and benign prostatic hyperplasia (BPH), and are associated with a poor disease outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2018.8778DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063028PMC
July 2018
4 Reads

Disparities in Hispanic/Latino and non-Hispanic Black men with low-risk prostate cancer and eligible for active surveillance: a population-based study.

Prostate Cancer Prostatic Dis 2018 11 9;21(4):533-538. Epub 2018 Jul 9.

Department of Urology, University of Miami, Miami, FL, USA.

Background: Non-Hispanic Black (NHB) men are at an increased risk for aggressive prostate cancer (PCa), making active surveillance (AS) potentially less optimal in this population. This concern has not been explored in other minority populations-specifically, Hispanic/Latino men. We recently found that Mexican-American men demonstrate an increased risk of PCa-specific mortality, and we hypothesized that they may also be at risk for an adverse outcome on AS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-018-0057-6DOI Listing
November 2018
6 Reads
3.425 Impact Factor

Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease.

Ann Oncol 2018 Aug;29(8):1814-1821

Research Center for Prostatic Pathologies (CeRePP), Paris, France.

Background: Management of localized prostate cancer (PCa) is a major clinical challenge since most of these cancers would not evolve but a majority of patients will still undergo a life-changing radical surgery. Molecular studies have shown that PCa can be classified according to their genomic alterations but none of the published PCa molecular classifications could identify a subtype corresponding to non-evolutive tumours.

Materials And Methods: Multi-omics molecular profiling was carried out on post-radical prostatectomy material from a cohort of 130 patients with localized PCa. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/annonc/article/29/8/1814/5045459
Publisher Site
http://dx.doi.org/10.1093/annonc/mdy224DOI Listing
August 2018
1 Read

Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database.

Adv Radiat Oncol 2018 Apr-Jun;3(2):170-180. Epub 2018 Jan 31.

Radiation Oncology Department, University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah.

Purpose: The aim of this study is to describe the trends and factors that influence the initial treatment of men with localized prostate cancer (PC) in the United States between 2004 and 2014.

Methods And Materials: The National Cancer Institute's Surveillance, Epidemiology and End Results database was used to identify patients with primary prostate adenocarcinoma between 2004 and 2014. Patients were staged in accordance with the American Joint Committee on Cancer 7th edition criteria and stratified according to the National Comprehensive Cancer Network guidelines risk group classification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2017.12.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000225PMC
January 2018
5 Reads

Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database.

Eur Urol Focus 2018 May 22. Epub 2018 May 22.

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.

Backround: Accurate life expectancy estimation is crucial in clinical decision-making including management and treatment of clinically localized prostate cancer (PCa).

Objective: We hypothesized that Social Security Administration (SSA) life tables' derived survival estimates closely follow observed survival of PCa patients. To test this relationship, we examined 10-yr overall survival rates in patients with clinically localized PCa and compared it with survival estimates derived from the SSA life tables. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2018.05.006DOI Listing
May 2018
12 Reads

Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.

JAMA 2018 05;319(18):1914-1931

Center for Healthcare Policy and Research, University of California, Davis, Sacramento.

Importance: Prostate cancer is the second leading cause of cancer death among US men.

Objective: To systematically review evidence on prostate-specific antigen (PSA)-based prostate cancer screening, treatments for localized prostate cancer, and prebiopsy risk calculators to inform the US Preventive Services Task Force.

Data Sources: Searches of PubMed, EMBASE, Web of Science, and Cochrane Registries and Databases from July 1, 2011, through July 15, 2017, with a surveillance search on February 1, 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2018.3712DOI Listing
May 2018
3 Reads

Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive cores.

Future Oncol 2018 Jun 10;14(15):1469-1476. Epub 2018 May 10.

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy El Sayed Street, Cairo, 11566, Egypt.

Aim: To develop a modified risk stratification scheme for localized prostate cancer incorporating percent of positive cores (PPC).

Methods: SEER database was accessed for eligible patients. Assessment of the prognostic value of PPC was conducted in a multivariate Cox regression model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0596DOI Listing
June 2018
2.480 Impact Factor

Active surveillance review: contemporary selection criteria, follow-up, compliance and outcomes.

Transl Androl Urol 2018 Apr;7(2):243-255

Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

The primary goal of active surveillance (AS) is to prevent overtreatment by selecting patients with low-risk prostate cancer (PCa) and closely monitoring them so that definitive treatment can be offered when needed. With the increasing popularity of AS as a management strategy for men with localized PCa, it is important to understand all the contemporary guidelines and criteria that exist for AS and the differences among them. No single optimal management strategy for clinically localized, early-stage disease has been universally accepted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2018.03.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911534PMC
April 2018
3 Reads

A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.

BJU Int 2018 Nov 3;122(5):783-793. Epub 2018 Jun 3.

Genitourinary Oncology Tumour Multidisciplinary Team, Departments of Cancer Imaging, Cancer Surgery and Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.

Background: Accurate staging of patients with prostate cancer (PCa) is important for therapeutic decision-making. Relapse after surgery or radiotherapy of curative intent is not uncommon and, in part, represents a failure of staging with current diagnostic imaging techniques to detect disease spread. Prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/computed tomography (CT) is a new whole-body scanning technique that enables visualization of PCa with high contrast. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14374DOI Listing
November 2018
14 Reads
1 Citation
3.533 Impact Factor

The Genomics of Prostate Cancer: A Historic Perspective.

Cold Spring Harb Perspect Med 2018 Apr 30. Epub 2018 Apr 30.

Englander Institute for Precision Medicine, Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York 10065.

The genomics of prostate cancer (PCA) has been difficult to study compared with some other cancer types for a multitude of reasons, despite significant efforts since the early 1980s. Overcoming some of these obstacles has paved the way for greater insight into the genomics of PCA. The advent of high-throughput technologies coming from the initial use of microsatellite and oligonucleotide probes gave rise to techniques like comparative genomic hybridization (CGH). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/cshperspect.a034942DOI Listing
April 2018
1 Citation
7.560 Impact Factor

[Oligometastatic prostate cancer. concept and implications.]

Arch Esp Urol 2018 Mar;71(3):239-246

UGC Urología. Hospital Universitario Reina Sofía/IMIBIC. Córdoba. España.

Oligometastatic prostate cancer has been proposed as an intermediate stage between localized and extensively disseminated disease. Oligometastatic disease is being diagnosed more frequently due to the advances in imaging tests. Nevertheless, there is no consensus definition yet of oligometastatic prostate cancer. Read More

View Article

Download full-text PDF

Source
March 2018
4 Reads

Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.

JAMA Oncol 2018 Jun 14;4(6):e180039. Epub 2018 Jun 14.

Cedars-Sinai Medical Center, Los Angeles, California.

Importance: Optimizing radiation therapy techniques for localized prostate cancer can affect patient outcomes. Dose escalation improves biochemical control, but no prior trials were powered to detect overall survival (OS) differences.

Objective: To determine whether radiation dose escalation to 79. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.0039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885160PMC
June 2018
6 Reads

National trends in management of localized prostate cancer: A population based analysis 2004-2013.

Prostate 2018 May 14;78(7):512-520. Epub 2018 Mar 14.

Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York.

Purpose: Recent years have brought many changes in the management of localized prostate cancer as national screening guidelines have been updated and diagnostic practice patterns evolved. We sought to better understand how the changing landscape influenced treatment utilization in the United States.

Methods: We used the SEER database in this retrospective analysis of patients with clinically localized prostate cancer between 2004 and 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23496DOI Listing
May 2018
6 Reads

Small Cell Carcinoma of Prostate: A Case Report of a Patient With Concomitant Transitional Cell Cancer of the Bladder.

J Investig Med High Impact Case Rep 2018 Jan-Dec;6:2324709618760644. Epub 2018 Mar 5.

Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, USA.

Small cell carcinomas (SCCs) are aggressive neoplasms commonly associated with a pulmonary origin. However, albeit rare, extrapulmonary SCC can occur in a variety of sites with an incidence in North America approximated to be 0.1% to 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2324709618760644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844437PMC
March 2018
8 Reads